OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential	372
Network pharmacology: curing causal mechanisms instead of treating symptoms	295
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic	275
Organ-on-a-Chip: A New Paradigm for Drug Development	231
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19	212
NLRP3 and pyroptosis blockers for treating inflammatory diseases	200
Causes and Consequences of Snake Venom Variation	187
Can Activation of NRF2 Be a Strategy against COVID-19?	156
In Vitro and Animal Models for SARS-CoV-2 research	149
A Perspective on Multi-target Drugs for Alzheimer’s Disease	147
Paving the Road for RNA Therapeutics	143
Tryptophan Metabolism as a Pharmacological Target	136
Emerging New Concepts of Degrader Technologies	116
Drug Repurposing for Rare Diseases	105
Metformin and Systemic Metabolism	105
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2	100
Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery	93
Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation	93
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor	89
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics	86
Iron metabolism: pathophysiology and pharmacology	85
Physiological and pharmacological modulation of BAX	84
Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration	80
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	78
Targeting the Immune System for Ischemic Stroke	72

Update and latest advances in antiretroviral therapy	72
AKAP Signaling Islands: Venues for Precision Pharmacology	70
Progranulin as a therapeutic target in neurodegenerative diseases	70
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades	69
Nrf2 for cardiac protection: pharmacological options against oxidative stress	65
Peptide–drug conjugate-based novel molecular drug delivery system in cancer	64
Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance	61
Tackling TAMs for Cancer Immunotherapy: It’s Nano Time	60
Recent breakthroughs and future directions in drugging aquaporins	60
Disrupting 3D printing of medicines with machine learning	59
Inhaled RNA Therapy: From Promise to Reality	57
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality	56
Deciphering the TCR Repertoire to Solve the COVID-19 Mystery	55
Advances and challenges in therapeutic targeting of NRF2	54
Charting the Fragmented Landscape of Drug Synergy	53
Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy	50
Circulating tumor cells in precision medicine: challenges and opportunities	48
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment	48
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics	46
Carbon Monoxide: from Poison to Clinical Trials	46
Polyunsaturated Fatty Acid Deuteration against Neurodegeneration	46
Affinity Hydrogels for Protein Delivery	42
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	41
Structural and Functional Insights into Cannabinoid Receptors	40
ER stress in obesity pathogenesis and management	39
RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets	38
Biomolecular Corona Affects Controlled Release of Drug Payloads from Nanocarriers	38
Biological Cells as Therapeutic Delivery Vehicles	37
Epigenetic Therapies for Osteoarthritis	37
Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity	36
Present and future of microglial pharmacology	36
High-power screening (HPS) empowered by DNA-encoded libraries	36
Opportunities and challenges for microRNA-targeting therapeutics for epilepsy	36
Structural perspective of class B1 GPCR signaling	35
Accessing Intracellular Targets through Nanocarrier-Mediated Cytosolic Protein Delivery	35
Autoantibodies as Endogenous Modulators of GPCR Signaling	35
Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine	35
Nanocarriers for oral delivery of biologics: small carriers for big payloads	35
Therapeutic RNA Strategies for Chronic Obstructive Pulmonary Disease	35
Small Molecule Drug Discovery for Neglected Tropical Snakebite	34
Targeting Two-Pore Channels: Current Progress and Future Challenges	34
Drug–Exposome Interactions: The Next Frontier in Precision Medicine	33
Modulation of Ion Channels and Receptors by p11 (S100A10)	33
Decoding pseudouridine: an emerging target for therapeutic development	33
CRISPR-based therapeutics: current challenges and future applications	32
Cancer Nanomedicines in an Evolving Oncology Landscape	32
Compstatins: the dawn of clinical C3-targeted complement inhibition	32
3D cell cultures toward quantitative high-throughput drug screening	32
Cholesterol – the devil you know; ceramide – the devil you don’t	31
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age	31

Acid-sensing ion channels as potential therapeutic targets	31
Dawn of a New RAMPage	30
Membrane protein production and formulation for drug discovery	30
Metastatic colorectal cancer: mechanisms and emerging therapeutics	30
14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases	29
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	29
Pharmacological tools to target NKCC1 in brain disorders	29
FOXO transcription factors as therapeutic targets in human diseases	29
Targeting natural killer cells to enhance vaccine responses	29
Mouse models of atherosclerosis in translational research	29
Computational and artificial intelligence-based methods for antibody development	29
Can Growth Factors Cure Parkinson’s Disease?	29
Single-Cell Techniques and Deep Learning in Predicting Drug Response	28
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the ‘Undruggable’ MYC in Pancreatic Cancer	28
The potential of long noncoding RNA therapies	28
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy	27
Biomolecular condensates: new opportunities for drug discovery and RNA therapeutics	26
Nanodelivery of cGAS-STING activators for tumor immunotherapy	26
Hypothalamic AMPK as a possible target for energy balance-related diseases	25
Discovery of De Novo Macrocyclic Peptides by Messenger RNA Display	25
Developing Insulin Delivery Devices with Glucose Responsiveness	25
Structural Biology of HIV Integrase Strand Transfer Inhibitors	25
Bridging the academia-to-industry gap: organ-on-a-chip platforms for safety and toxicology assessment	25
Targeting intracellular protein–protein interactions with macrocyclic peptides	24
Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs	24
Nanomedicine: controlling nanoparticle clearance for translational success	24
AI-powered therapeutic target discovery	24
Clinical Implications of Folate Transport in the Central Nervous System	23
Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells	23
Fragment-based drug design facilitates selective kinase inhibitor discovery	23
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	23
Engineered antibody fusion proteins for targeted disease therapy	23
Mitochondrial dynamics proteins as emerging drug targets	23
Targeting SARS-CoV-2 papain-like protease in the postvaccine era	22
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	22
Engineering ACE2 decoy receptors to combat viral escapability	22
Targeting of Potassium Channels in Cardiac Arrhythmias	22
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic	22
Anticancer opportunities at every stage of chemokine function	22
Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives	21
Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future	21
Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent	21
Histone post-translational modifications as potential therapeutic targets for pain management	21
The Convergence of Extracellular Vesicle and GPCR Biology	21
Modulating the Blood–Testis Barrier Towards Increasing Drug Delivery	21
Structure-Based Virtual Screening Accelerates GPCR Drug Discovery	21
Microfluidic technologies for drug discovery and development: friend or foe?	21
Ferrous Iron-Dependent Pharmacology	20
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	20
Advances in Targeting GIRK Channels in Disease	20
Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions	19
Targeting the mitochondrial chaperone TRAP1: strategies and therapeutic perspectives	19
Pharmacogenomics in treatment of depression and psychosis: an update	19
Delivering AAV to the Central Nervous and Sensory Systems	18
Modulation of T cells by tryptophan metabolites in the kynurenine pathway	18
Adenosine and inflammation: it's time to (re)solve the problem	18
Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics	18
Deep mutational scanning for therapeutic antibody engineering	18
Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells	18
BH3 Mimetics in AML Therapy: Death and Beyond?	18